FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF C | HANGES | IN BEN | IEFICIAL | OWNER | SHIP |
|-----------|------|--------|--------|----------|-------|------|
|           |      |        |        |          |       |      |

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Anicetti Vincent R</u>   |       |  | 2. Issuer Name <b>and</b> Ticker or Trading Symbol Coherus BioSciences, Inc. [ CHRS ] |                                   |   |  |   |  |             |  | Relationship<br>heck all appl<br>Direct | icable)   | g Pers   | on(s) to Issi<br>10% Ow<br>Other (s                               | ner  |                                       |   |
|--|-------|--|---|-----------------------------------|---|--|---|--|-------------|--|---|---|--|---|--|---------------------------------------|---|
| (Last) (First) (Middle) COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600  |       |  |   |                                   | 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2018 |  |   |  |             |  |   |   | below  |   | & Co   | below)                                | · |
| (Street) REDWO   | OOD C | A  | 94065   |                                   | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |  |   |  |             |  | ne)<br>X Form<br>Form                   |   |  |   |  |                                       |   |
| (City)   | (S    | tate)  | (Zip)   |                                   |   |  |   |  |             |  |   |   |  |   |  |                                       |   |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned   |       |  |   |                                   |   |  |   |  |             |  |   |   |  |   |  |                                       |   |
| Date   |       |  | t. Transact<br>Date<br>Month/Day  | Execution Date,                   |   | 3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) |   |  |             | Benefic  | es<br>ially<br>Following                | Form:<br>(D) or                                     | rm: Direct<br>or Indirect<br>(Instr. 4)  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |                                       |   |
|  |       |  |   |                                   |   | Code   | v | Amount   | t (A) or Pi |  | Transac<br>(Instr. 3                    | ction(s)  |  |   | instr. 4)  |                                       |   |
| Common Stock, \$0.0001 par value   |       |  |   |                                   |   |  |   |  |             |  | 5,150                                   |   |  | D   |  |                                       |   |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |       |  |   |                                   |   |  |   |  |             |  |   |   |  |   |  |                                       |   |
| Derivative   Conversion   Date   |       | 3. Transaction Date (Month/Day/Year)  3. Deemed Execution D if any (Month/Day/ |   | Date, Transaction<br>Code (Instr. |   | n of   |   | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |             | 7. Title and Amoun<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |   | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | lly   | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4) |   |
|  |       |  |   | Cod                               | e V   | (A)  |   | Date<br>Exercisable  |             | xpiration<br>ate   | Title                                   | Amount<br>or<br>Number<br>of<br>Shares              | 1  |   |  |                                       |   |
| Stock<br>Option<br>(Right to<br>Buy)   | \$9.8 | 03/01/2018   |   | A                                 |   | 25,000   |   | (1)  | 0           | 3/01/2028  | Common<br>Stock                         | 25,000  | \$0.00   | 25,000  | )  | D                                     |   |

## **Explanation of Responses:**

1. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

## Remarks:

/s/ Jean Frederic Viret, as Attorney-in-Fact for Vincent R. 03/05/2018 Anicetti

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.